The FDA has accepted for filing the sBLA for omalizumab for the treatment of adults with chronic rhinosinusitis with nasal polyps who have had an inadequate response to intranasal corticosteroids.
The fluticasone exhalation delivery system is a novel topical steroid delivery system that is an important adjunct therapy for sinonasal inflammatory disease.
The Food and Drug Administration (FDA) has approved Dupixent (dupilumab; Sanofi and Regeneron) as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis.
There is no significant increased benefit in using a higher-dose nasal steroid spray compared with the standard dose after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis.
Patients with chronic rhinosinusitis with nasal polyps who had a higher concentration of Charcot-Leyden crystals in nasal secretions were more likely to respond to glucocorticoid therapy.
Patients with chronic rhinosinusitis with nasal polyps experienced improvements in endoscopic, radiologic, and clinical outcomes when treated with dupilumab as add-on therapy to intranasal mometasone furoate.
Haemophilus influenzae, Staphylococcus aureus, and Streptococcus pyogenes were found in approximately one-fifth of isolated IgE antibodies via plasmablasts residing in nasal polyps.
